Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease

January 10, 2011 By Bio-Medicine.Org

NATICK, Mass., Jan. 10, 2011 /PRNewswire/ — Boston Scientific
Corporation (NYSE:
BSX
) today announced that it has completed enrollment in the
ORION clinical trial, which is designed to evaluate the Company’s
EPIC™ Self-Expanding Nitinol Stent System for the treatment
of iliac artery disease, a form of peripheral artery disease
associated with severe leg pain caused by insufficient blood flow
to the muscles (claudication).  The trial will examine rates
of device- and/or procedure-related major adverse events and
patency rates at nine months in 125 patients at 28 sites in the
United States.  

“We are pleased to complete the enrollment phase of this
important trial,” said Daniel Clair, M.D., F.A.C.S., Chairman of
the Department of Vascular Surgery, The Cleveland Clinic
Foundation, and Principal Investigator of the trial.
 “Peripheral stenting has become a recognized standard in the
treatment of iliac artery disease, and the ORION trial will provide
important data on the performance of the EPIC Stent in treating
these types of lesions.”

The next-generation EPIC Stent is a self-expanding nitinol stent
designed to sustain vessel patency, while providing enhanced
visibility and accuracy during placement.  It employs an
innovative Radial Tandem Architecture™, which is engineered
to provide stent flexibility while maintaining predictable radial
force characteristics across the entire stent size matrix.
 The ORION trial incorporates stent diameter ranges from 6 to
12 mm and lengths up to 120 mm.  All stent sizes are
compatible with 6F (2.1 mm) sheaths, and the stent delivery system
is compatible with 0.035 inch (0.89 mm) guidewires.

“We are encouraged by the success of our EPIC Stent since its
European approval and launch in early 2009, and we look forward to
its approval in the U.S. based on results from this trial,” said
Joe Fi

‘/>”/>

SOURCE

Related Articles Read More >

UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech